Summary
Vertex Pharmaceuticals Inc. reported a significant net loss of $308.0 million for the first quarter of 2013, a sharp contrast to the $91.6 million net income in the same period of 2012. This loss was primarily driven by a substantial $412.9 million intangible asset impairment charge related to their VX-222 asset. Total revenues also declined by 25% year-over-year to $328.4 million, largely due to a 29% decrease in product revenues, with INCIVEK sales showing a notable drop, though partially offset by growth in KALYDECO. Despite the reported net loss and revenue decline, the company maintains a strong liquidity position with $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2013. Investment in research and development increased by 11% to $218.1 million, underscoring Vertex's commitment to its pipeline, particularly in Cystic Fibrosis and Hepatitis C. The company is strategically focusing on KALYDECO's growth and advancing its pipeline candidates to mitigate the expected continued decline in INCIVEK revenues.
Financial Highlights
48 data points| Revenue | $328.37M |
| Cost of Revenue | $30.95M |
| Gross Profit | $297.41M |
| R&D Expenses | $210.20M |
| SG&A Expenses | $91.63M |
| Operating Expenses | $757.51M |
| Operating Income | -$429.14M |
| Net Income | -$308.02M |
| EPS (Basic) | $-1.43 |
| EPS (Diluted) | $-1.43 |
| Shares Outstanding (Basic) | 215.42M |
| Shares Outstanding (Diluted) | 215.42M |
Key Highlights
- 1Reported a net loss of $308.0 million for Q1 2013, compared to a net income of $91.6 million in Q1 2012, largely due to a $412.9 million intangible asset impairment charge for VX-222.
- 2Total revenues decreased by 25% to $328.4 million in Q1 2013, driven by a 29% decline in product revenues.
- 3INCIVEK net product revenues decreased significantly by $151.4 million year-over-year, while KALYDECO net product revenues increased by $43.4 million.
- 4Research and development expenses increased by 11% to $218.1 million, reflecting continued investment in the company's pipeline.
- 5Maintained a strong liquidity position with $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2013.
- 6The company anticipates further declines in INCIVEK revenues due to evolving market dynamics in Hepatitis C treatment.
- 7VX-661, a CFTR corrector, showed positive results in combination with ivacaftor in a Phase 2 trial, with statistically significant improvements in lung function.